Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Edivoxetine

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Mechanistic Studies of the N-formylation of Edivoxetine, a Secondary Amine-Containing Drug, in a Solid Oral Dosage Form.
Edivoxetine (LY2216684 HCl), although a chemically stable drug substance, has shown the tendency to degrade in the presence of… Expand
  • figure 1
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
2016
2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor…
OBJECTIVE Three studies examined whether edivoxetine (a highly selective norepinephrine reuptake inhibitor) had efficacy as… Expand
Is this relevant?
2015
2015
A pharmacokinetic/pharmacodynamic investigation: Assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter…
Inhibition of norepinephrine (NE) reuptake into noradrenergic nerves is a common therapeutic target in the central nervous system… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.
Norepinephrine, a neurotransmitter in the autonomic sympathetic nervous system, is deaminated by monoamine oxidase to 3,4… Expand
Is this relevant?
2014
2014
A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor…
BACKGROUND This phase 2 study examined the efficacy and tolerability of edivoxetine, a highly selective norepinephrine reuptake… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE The purpose of this study was to assess the efficacy and safety of edivoxetine (LY2216684), a selective norepinephrine… Expand
Is this relevant?
Review
2013
Review
2013
Novel agents in development for the treatment of depression.
There are several investigational drugs in development for the treatment of depression. Some of the novel antidepressants in… Expand
Is this relevant?
2013
2013
Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE The purpose of this study was to assess the clinical outcomes from an open label study of edivoxetine, a selective… Expand
Is this relevant?
2013
2013
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
PurposeTo assess the impact of hepatic or renal impairment on the pharmacokinetics (PK) of edivoxetine.MethodsTwo separate multi… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
Is this relevant?
2012
2012
Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE Edivoxetine (LY2216684) is a selective and potent norepinephrine reuptake inhibitor (NERI). The pharmacokinetics (PK… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE